JP2018512047A - 汎用キラーt細胞 - Google Patents
汎用キラーt細胞 Download PDFInfo
- Publication number
- JP2018512047A JP2018512047A JP2017557481A JP2017557481A JP2018512047A JP 2018512047 A JP2018512047 A JP 2018512047A JP 2017557481 A JP2017557481 A JP 2017557481A JP 2017557481 A JP2017557481 A JP 2017557481A JP 2018512047 A JP2018512047 A JP 2018512047A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- tcr
- modified
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 423
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 183
- 239000000427 antigen Substances 0.000 claims abstract description 123
- 108091007433 antigens Proteins 0.000 claims abstract description 121
- 102000036639 antigens Human genes 0.000 claims abstract description 121
- 230000002163 immunogen Effects 0.000 claims abstract description 50
- 239000003814 drug Substances 0.000 claims abstract description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 103
- 201000011510 cancer Diseases 0.000 claims description 78
- 230000014509 gene expression Effects 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 18
- 238000009172 cell transfer therapy Methods 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 108700010039 chimeric receptor Proteins 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 abstract description 206
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract description 205
- 210000000987 immune system Anatomy 0.000 abstract description 8
- 230000003013 cytotoxicity Effects 0.000 abstract description 5
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 43
- 210000001744 T-lymphocyte Anatomy 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 35
- 230000001472 cytotoxic effect Effects 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 230000028993 immune response Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 12
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- 230000010076 replication Effects 0.000 description 11
- 230000011664 signaling Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 231100000433 cytotoxic Toxicity 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 7
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 102000006306 Antigen Receptors Human genes 0.000 description 6
- 108010083359 Antigen Receptors Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 230000037433 frameshift Effects 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 108010001041 HLA-DR7 Antigen Proteins 0.000 description 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 102000054766 genetic haplotypes Human genes 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 239000013638 trimer Substances 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000021309 Germ cell tumor Diseases 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 210000003967 CLP Anatomy 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 208000006402 Ductal Carcinoma Diseases 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 241000242711 Fasciola hepatica Species 0.000 description 2
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010067517 Pancreatic neuroendocrine tumour Diseases 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 208000033014 Plasma cell tumor Diseases 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 208000008938 Rhabdoid tumor Diseases 0.000 description 2
- 206010073334 Rhabdoid tumour Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000006275 fascioliasis Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000000564 macroglobulinemia Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 208000010626 plasma cell neoplasm Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- YVOOPGWEIRIUOX-UHFFFAOYSA-N 2-azanyl-3-sulfanyl-propanoic acid Chemical compound SCC(N)C(O)=O.SCC(N)C(O)=O YVOOPGWEIRIUOX-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 102000041068 Class II family Human genes 0.000 description 1
- 108091060782 Class II family Proteins 0.000 description 1
- 241001327965 Clonorchis sinensis Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010057649 Endometrial sarcoma Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000282576 Pan paniscus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010055006 Pancreatic sarcoma Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 108010055790 immunoglobulin B Proteins 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000008893 intraocular retinoblastoma Diseases 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000002526 pancreas sarcoma Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000010639 renal pelvis urothelial carcinoma Diseases 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 208000037968 sinus cancer Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- -1 that is Proteins 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000000334 ureter transitional cell carcinoma Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46443—Growth factors
- A61K39/464434—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
(a)CD3を発現するように改変された非免疫原性のNK細胞を提供し;
(b)治療される被験体のMHC型を決定し;
(c)例えば被験体内のがんのタイプおよび/または特定のがんマーカー(抗原など)の発現や特定の変異の有無等を特定または決定することにより、被験体の細胞によって発現または提示されている被験体内の標的抗原を特定し;
(d)標的抗原に対して特異性を有し、且つ被験体のMHC型に適合するTcRを発現するように、工程(a)の細胞を改変する。
a)非免疫原性であるNK細胞を提供すること、より具体的にはNK細胞を非免疫原性に改変し;および
b)CD3を発現するように前記細胞を改変する。
前記方法は以下の工程を含む:
a)例えばNK細胞を非免疫原性に改変するなど、非免疫原性であるNK細胞を提供し;
b)CD3を発現するように前記細胞を改変し;
c)がん特異的TcRを発現するように前記細胞を改変する。
(a)非免疫原性であり且つCD3を発現する改変汎用NK細胞、より具体的には非免疫原性となるように且つCD3を発現するように改変されたNK細胞;および
(b)それぞれのTcRが様々な抗原特異性および/または様々なMHC特異性を有する、TcRをコードする核酸分子のパネル。
a)NK細胞をCD3を発現するように改変する;
b)前記標的細胞のMHCプロファイルおよび前記標的細胞により提示された抗原の同一性を決定する;
c)それぞれのTcRが様々な抗原および/またはMHC型に対して特異性を有するパネルから選択されたTcRであって、MHCおよび前記標的細胞に提示された抗原に対して特異性を有するTcRを発現するような前記NK細胞を改変する。
NK92細胞におけるCD3の発現
CD3をNK92細胞にトランスフェクションするためにコドン最適化pMP71−CD3ζ−CD3ε−CD3γ−CD3δ−IRES−GFP(CD3−GFP)ベクター(Ahmadi et al. 2011. Blood 118, 3528-3573)を用い、細胞レトロウィルス導入を用いるてトランスフェクトした。CD3−GFPコンストラクトを担持したレトロウイルスはパッケージング細胞株(Hek−Phoenix)により産生され、およびNK細胞はスピノキュレーション(spinoculation)(0.3Mの細胞ウイルス上清と共にインキュベートし、レトロネクチン(登録商標)(Tanaka Biotech)でコーティングしたプレート上で32℃で1時間、900×gでスピンダウンした)を行った。形質導入が成功したことを示すためのマーカーとしてはGFPを用いた。
NK−92(CD3)細胞におけるTcRの発現
NK−92(CD3)細胞におけるCD3およびTcRの共発現の能力を評価した。細胞表面を標的にするために、CD3およびTcRはそれぞれ、TcR複合体の他のメンバーの共発現を必要とする。したがって、NK細胞の表面上におえるCD3の発現を、CD3およびTcRの両方が共発現できたことへのマーカーとして用いることができる。
TcR発現NK−92(CD3)は機能を有する
NK細胞に発現したTcRの機能を確かめるために、NK細胞に発現したTcRが標的細胞を特異的に認識できるかどうかを確認した。
TcR発現NK−92(CD3)細胞の関連ペプチドをロードしたT2細胞による活性化
NK−92(CD3)細胞をRadium−1またはDMF−5TcRのいずれかを発現するように改変し、細胞表面のCD3の発現は、APC−標識抗CD3抗体を用いて検出した。脱顆粒解析のためにCD3+細胞を選択して(図5、上のパネル)ソートした。
NK−92(CD3)細胞におけるTcR/CD3介在性シグナル伝達
Radium−1 TcRをトランスフェクションしたNK−92(CD3)細胞について、それらのシグナル伝達能を調べるためにPhospho−フローサイトメトリーを用いて評価を行った。最初に、TCRを通じて活性化を刺激する、抗CD3抗体および抗CD28抗体で細胞を刺激することにより、通常のTCR複合体のシグナル伝達能力を解析した。図7に示すように、TcRおよびCD3がクラスター化することで、T細胞において観察されたのと同じようにシグナル伝達カスケードを活性化した。これはいくつかのZAP−70、SLP−76andCD3ζなどのTcR/CD3−関連タンパク質のリン酸化レベルの増加により示されている。
CD4 + T細胞由来のTcRによるNK−92(CD3)細胞の刺激
NK−92(CD3)細胞に、CD4+T細胞由来のTcRであるRadium5およびRadium6を形質導入した。これらのTcRはMHCクラスIIペプチド標的に対して細胞を特異的に再指向することができた。Radium−5およびRadium−6のいずれも特異的にTGFbRIIフレームシフト変異ペプチド(KSLVRLSSCVPVALMSAMT)を標的とする;Radium−5はHLA−DR7の存在下で、Radium−6はHLA−DR4で、このペプチドを特異的に標的にする。NK−92(CD3)−Radium5/6細胞における刺激のキネティックスは図9に示す。上記実施例4と同様にNK−92(CD3)細胞刺激を測定した。それぞれのTcRのEC50値を図9に示すように算出した。HLA−DR7ハプロタイプの患者の試料におけるRadium−5のEC50は19μMと算出された;ある患者におけるRadium6のEC50は4μMであり、次の患者は0.4μMと算出された。いずれの患者試料もBHLA−DR4ハプロタイプであった。
CD3/CD3−TcR発現の有無におけるNK−92タンパク質の発現の解析
NK−92細胞のタンパク質発現プロファイルを、NK92(CD3/CD3−TcR)細胞と比較した。2つの細胞集団の間に違いは見られなかった(言うまでもなくNK−92(CD3/CD3−TcR)細胞にCD3が存在していることを除く。比較したものを以下の表に示す(PBMC=末梢血単核細胞)。
Claims (22)
- 改変NK細胞であって、
前記細胞が非免疫原性であり、CD3を発現するように改変された細胞であり、
前記CD3が、TcR−CD3融合体以外のキメラ受容体の一部としては発現されない、改変NK細胞。 - 前記細胞が非免疫原性であるように改変された、請求項1の細胞。
- 前記細胞が改変NK−92細胞である、請求項1または2の細胞。
- 前記細胞が照射を受けているか、
または前記細胞の増殖能がその他の方法で抑制されている、請求項1〜3のいずれか一項の細胞。 - 前記細胞が、β2ミクログロブリンの発現を抑制または阻害するように改変されている、請求項1〜4のいずれか1項の細胞。
- 前記細胞が、標的細胞上の抗原に対して特異性を有するTcRを発現するように、さらに改変されている、請求項1〜5のいずれか一項の細胞。
- 前記TcRが共受容体非依存性である、請求項6の細胞。
- 前記標的細胞ががん細胞である、請求項4〜6のいずれか一項の細胞。
- 前記標的細胞が感染細胞である、請求項4〜6のいずれか一項の細胞。
- 治療における使用のための、請求項4〜8のいずれか1項に記載の細胞。
- 養子細胞移入療法における使用のための、請求項4〜8のいずれか一項の細胞。
- がんの治療における使用のための、請求項10の細胞。
- 前記TcRが、処理される被験体の標的細胞において発現している抗原と、前記被験体のMHCタイプとの双方に特異的である、請求項9〜11のいずれか一項の細胞。
- 養子細胞移入療法において使用するための医薬の製造における改変NK細胞の使用であって、好ましくは前記療法ががんの治療である、請求項4〜12のいずれか一項で規定された改変NK細胞の使用。
- 少なくとも1つの薬学的に許容される、担体または賦形剤と共に、請求項4〜12のいずれか一項の改変NK細胞を含む、治療用組成物。
- 請求項4〜12のいずれか1項の改変NK細胞の有効量を、それを必要とする対象に投与することを含む、治療方法。
- 養子細胞移入療法のための細胞の調製において使用するための汎用NK細胞の製造方法であって、
(a)非免疫原性NK細胞を提供する工程;および
(b)前記細胞を改変してCD3を発現させる工程
を含む、方法。 - 治療用途のための、改変NK細胞を調製するための方法であって、
(a)CD3を発現するように改変された非免疫原性NK細胞を提供し;
(b)処理を行う被験体のMHC型を決定し;
(c)前記被験体内の細胞によって発現または提示される抗原である、前記被験体内の標的抗原を特定し;
(d)前記標的抗原に対する特異性を有するTcRを発現させるために工程(a)の細胞を改変し、
前記被験体のMHC型と適合させる、
方法。 - 前記TcRががん抗原に特異的である、請求項17の方法。
- 養子細胞移入療法に使用するためのキットであって、
(a)請求項1〜5のいずれか一項に記載の改変された汎用NK細胞;および
(b)それぞれがTcRをコードする核酸分子のパネルであって、前記TcRが異なる抗原特異性および/または異なるMHC特異性を有するパネル、
を含むキット。 - 前記核酸分子がベクター、好ましくはウイルスベクターに含まれる、請求項19のキット。
- それぞれのNK細胞が非免疫原性であり、CD3およびTcRを発現するように改変された、改変NK細胞のパネルであって、前記それぞれのNK細胞のTcRが異なった抗原特異性および/または異なったMHC特異性を有している、パネル。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1501175.2A GB201501175D0 (en) | 2015-01-23 | 2015-01-23 | A universal T-cell for personalised medicine |
GB1501175.2 | 2015-01-23 | ||
PCT/EP2016/051344 WO2016116601A1 (en) | 2015-01-23 | 2016-01-22 | Universal killer t-cell |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018512047A true JP2018512047A (ja) | 2018-05-10 |
JP2018512047A5 JP2018512047A5 (ja) | 2019-03-07 |
JP6899333B2 JP6899333B2 (ja) | 2021-07-07 |
Family
ID=52673865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017557481A Active JP6899333B2 (ja) | 2015-01-23 | 2016-01-22 | 汎用キラーt細胞 |
Country Status (17)
Country | Link |
---|---|
US (2) | US11155786B2 (ja) |
EP (2) | EP3247791B1 (ja) |
JP (1) | JP6899333B2 (ja) |
KR (1) | KR102479118B1 (ja) |
CN (1) | CN107250351A (ja) |
AU (2) | AU2016208475B2 (ja) |
CA (1) | CA2973924A1 (ja) |
DK (1) | DK3247791T3 (ja) |
EA (1) | EA201791381A1 (ja) |
ES (1) | ES2922231T3 (ja) |
GB (1) | GB201501175D0 (ja) |
IL (1) | IL253464B (ja) |
MX (1) | MX2017009459A (ja) |
PL (1) | PL3247791T3 (ja) |
PT (1) | PT3247791T (ja) |
SG (1) | SG11201705693XA (ja) |
WO (1) | WO2016116601A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2017192440A1 (en) * | 2016-05-02 | 2017-11-09 | Cerus Corporation | Compositions and methods for improved nk cell therapies |
CN109715668A (zh) | 2016-08-02 | 2019-05-03 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重编程的组合物和方法 |
PT3445787T (pt) | 2016-10-07 | 2021-03-15 | Tcr2 Therapeutics Inc | Composições e métodos para reprogramação de recetores de célula t com o uso de proteínas de fusão |
CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
US20190358263A1 (en) | 2016-12-07 | 2019-11-28 | Oslo Universitetssykehus Hf | Compositions and Methods for Cell Therapy |
EP3565565A4 (en) * | 2017-01-04 | 2020-12-09 | Nova Southeastern University | NATURAL KILLER CELLS (NK) FOR THE EXPRESSION OF AN ANTIGENS-SPECIFIC FUNCTIONAL T-CELL RECEPTOR (TCR) COMPLEX, METHOD FOR MANUFACTURING THEREOF AND METHOD FOR THERAPEUTIC USE THEREOF |
KR20210111745A (ko) * | 2018-08-31 | 2021-09-13 | 잉벡띠스 에스아 | Car 기능성을 평가하는 방법 |
JP6977969B2 (ja) * | 2019-03-22 | 2021-12-08 | 株式会社ガイアバイオメディシン | 免疫細胞提供システム |
EP3750547A1 (en) | 2019-06-13 | 2020-12-16 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Modified nk-92 cells, and therapeutic and diagnostic uses thereof |
CN111662871A (zh) * | 2020-06-11 | 2020-09-15 | 福建医科大学孟超肝胆医院(福州市传染病医院) | 一种核酸适体功能化nk细胞及其制备与应用 |
AU2021348239A1 (en) | 2020-09-24 | 2023-05-04 | Medigene Immunotherapies Gmbh | Prame specific t-cell receptors and uses thereof |
TW202233831A (zh) * | 2020-11-03 | 2022-09-01 | 中國大陸商杭州啟函生物科技有限公司 | 增強免疫療法的系統和方法 |
GB202017873D0 (en) | 2020-11-12 | 2020-12-30 | Olso Unversitetssykehus Hf | Method of determining DLBCL prognosis |
KR20220160479A (ko) * | 2021-05-27 | 2022-12-06 | (주)에스엠티바이오 | 신경내분비종양의 치료용 자연살해세포 |
WO2023047089A1 (en) | 2021-09-21 | 2023-03-30 | Oslo Universitetssykehus Hf | Binding proteins for terminal deoxynucleotidyl transferase (tdt) |
WO2023078287A1 (en) * | 2021-11-03 | 2023-05-11 | Hangzhou Qihan Biotechnology Co., Ltd. | Systems and methods for enhanced immunotherapies |
WO2024020537A2 (en) * | 2022-07-22 | 2024-01-25 | Board Of Regents, The University Of Texas System | Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015223143A (ja) * | 2014-05-29 | 2015-12-14 | 国立大学法人富山大学 | Tcrの細胞傷害活性誘導能を評価するためのnk細胞株、およびその作製方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5124251A (en) | 1990-01-31 | 1992-06-23 | Becton, Dickinson And Company | CD3 ζ co-associated complex on CD16- NK cells |
EP1690927A1 (en) | 1997-04-30 | 2006-08-16 | Hans Klingemann | Natural killer cell lines and methods of use |
IL127142A0 (en) | 1998-11-19 | 1999-09-22 | Yeda Res & Dev | Immune cells having predefined biological specificity |
JP4716350B2 (ja) | 2001-12-04 | 2011-07-06 | ダナ−ファーバー キャンサー インスティテュート インク. | 潜伏期膜タンパク質に対する抗体およびそれらの使用 |
DK2921500T3 (da) | 2004-07-10 | 2023-09-18 | The Institute For Cancer Res | Genetisk modificerede, humane, naturlige dræbercellelinjer |
JP5525689B2 (ja) * | 2004-11-02 | 2014-06-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 過剰増殖性障害を処置するための組成物および方法 |
US8518697B2 (en) | 2006-04-04 | 2013-08-27 | Washington University | Single chain trimers and uses therefor |
CN101631138A (zh) | 2008-07-18 | 2010-01-20 | 深圳富泰宏精密工业有限公司 | 个人信息代理系统及方法 |
US8785601B2 (en) * | 2009-01-28 | 2014-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
US10247731B2 (en) * | 2012-02-22 | 2019-04-02 | Verik Bio, Inc. | System for immunotherapy targeting tumor propagation and progression |
US11471486B2 (en) | 2012-09-04 | 2022-10-18 | Inven2 As | Selective and controlled expansion of educated NK cells |
US9511092B2 (en) | 2013-01-28 | 2016-12-06 | St. Jude Children's Research Hospital, Inc. | Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease |
AU2014212009B2 (en) | 2013-02-04 | 2020-01-30 | Roger Williams Medical Center | Methods and compositions for treating gastrointestinal stromal tumor (GIST) |
AU2015276136A1 (en) | 2014-06-18 | 2016-12-22 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Car-expressing NK-92 cells as cell therapeutic agents |
US20170274014A1 (en) * | 2014-07-21 | 2017-09-28 | Jennifer Brogdon | Combinations of low, immune enhancing, doses of mtor inhibitors and cars |
-
2015
- 2015-01-23 GB GBGB1501175.2A patent/GB201501175D0/en not_active Ceased
-
2016
- 2016-01-22 JP JP2017557481A patent/JP6899333B2/ja active Active
- 2016-01-22 AU AU2016208475A patent/AU2016208475B2/en active Active
- 2016-01-22 SG SG11201705693XA patent/SG11201705693XA/en unknown
- 2016-01-22 PL PL16701339.0T patent/PL3247791T3/pl unknown
- 2016-01-22 EP EP16701339.0A patent/EP3247791B1/en active Active
- 2016-01-22 US US15/545,021 patent/US11155786B2/en active Active
- 2016-01-22 WO PCT/EP2016/051344 patent/WO2016116601A1/en active Application Filing
- 2016-01-22 EP EP22170488.5A patent/EP4095239A1/en active Pending
- 2016-01-22 DK DK16701339.0T patent/DK3247791T3/da active
- 2016-01-22 CN CN201680006587.4A patent/CN107250351A/zh active Pending
- 2016-01-22 ES ES16701339T patent/ES2922231T3/es active Active
- 2016-01-22 PT PT167013390T patent/PT3247791T/pt unknown
- 2016-01-22 CA CA2973924A patent/CA2973924A1/en active Granted
- 2016-01-22 EA EA201791381A patent/EA201791381A1/ru unknown
- 2016-01-22 MX MX2017009459A patent/MX2017009459A/es unknown
- 2016-01-22 KR KR1020177023284A patent/KR102479118B1/ko active IP Right Grant
-
2017
- 2017-07-13 IL IL253464A patent/IL253464B/en unknown
-
2021
- 2021-09-23 US US17/483,484 patent/US20220127574A1/en active Pending
-
2022
- 2022-01-11 AU AU2022200126A patent/AU2022200126A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015223143A (ja) * | 2014-05-29 | 2015-12-14 | 国立大学法人富山大学 | Tcrの細胞傷害活性誘導能を評価するためのnk細胞株、およびその作製方法 |
Non-Patent Citations (4)
Title |
---|
HALL C ET AL.: "Requirements for cell surface expression of the human TCR/CD3 complex in non-T cells", INT IMMUNOL., vol. 3(4), JPN6019042117, 1991, pages 359 - 368, ISSN: 0004144311 * |
KNORR DA ET AL.: "Pluripotent stem cell-derived natural killer cells for cancer therapy", TRANSL RES., vol. 156(3), JPN6019042116, 2010, pages 147 - 154, ISSN: 0004144310 * |
LANIER LL ET AL.: "Expression of cytoplasmic CD3 epsilon proteins in activated human adult natural killer (NK) cells an", J IMMUNOL., vol. 149(6):, JPN6019042113, 1992, pages 1876 - 1880, XP055511034, ISSN: 0004144309 * |
TAM YK ET AL.: "Ex vivo expansion of the highly cytotoxic human natural killer cell line NK-92 under current good ma", CYTOTHERAPY, vol. 5(3), JPN6019042111, 2003, pages 259 - 272, ISSN: 0004144308 * |
Also Published As
Publication number | Publication date |
---|---|
GB201501175D0 (en) | 2015-03-11 |
ES2922231T3 (es) | 2022-09-12 |
CA2973924A1 (en) | 2016-07-28 |
WO2016116601A1 (en) | 2016-07-28 |
CN107250351A (zh) | 2017-10-13 |
KR102479118B1 (ko) | 2022-12-16 |
JP6899333B2 (ja) | 2021-07-07 |
NZ733855A (en) | 2023-10-27 |
KR20170121178A (ko) | 2017-11-01 |
EP3247791B1 (en) | 2022-05-04 |
BR112017015631A2 (pt) | 2018-03-13 |
AU2022200126A1 (en) | 2022-02-10 |
EA201791381A1 (ru) | 2018-02-28 |
US20180010097A1 (en) | 2018-01-11 |
MX2017009459A (es) | 2018-04-11 |
IL253464A0 (en) | 2017-09-28 |
AU2016208475B2 (en) | 2021-10-14 |
EP4095239A1 (en) | 2022-11-30 |
IL253464B (en) | 2022-04-01 |
PT3247791T (pt) | 2022-07-20 |
SG11201705693XA (en) | 2017-08-30 |
US11155786B2 (en) | 2021-10-26 |
AU2016208475A1 (en) | 2017-08-03 |
DK3247791T3 (da) | 2022-07-11 |
PL3247791T3 (pl) | 2022-09-05 |
EP3247791A1 (en) | 2017-11-29 |
US20220127574A1 (en) | 2022-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220127574A1 (en) | Universal Killer T-Cell | |
Li et al. | Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity | |
JP6884155B2 (ja) | 癌治療のための併用免疫療法及びサイトカイン制御療法 | |
US11304978B2 (en) | Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy | |
JP6858128B2 (ja) | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ | |
KR102489954B1 (ko) | 인간 백혈구 항원 제한된 감마 델타 t 세포 수용체 및 이의 사용 방법 | |
JP2021113200A (ja) | 能動的細胞免疫療法のためのサイトカイン組成物を用いたリンパ球の増殖 | |
TW201928052A (zh) | 靶向ny-eso-1的基因修飾免疫細胞及其用途 | |
TW201619377A (zh) | Car表現載體及car表現t細胞 | |
JP2020527937A (ja) | 新規の細胞タグの発現 | |
JP2015509717A (ja) | 抗腫瘍活性およびcar存続性を強化するためのicosベースのcarの使用 | |
KR20150002706A (ko) | 종양 형성 치료방법 | |
US20190091310A1 (en) | Nonreleased il-12 for therapy of cancer | |
KR20210057750A (ko) | 암 면역치료요법을 위한 mr1 제한된 t 세포 수용체 | |
TW202039540A (zh) | 一種治療ebv相關性癌症之抗lmp2 tcr-t細胞療法 | |
CN109891238A (zh) | 免疫治疗剂的剂量确定 | |
CA2973924C (en) | Universal killer t-cell | |
EA040420B1 (ru) | Универсальная клетка т-киллер | |
BR112017015631B1 (pt) | Uso de uma célula nk modificada, composição terapêutica, métodos para a produção de uma célula nk universal e para preparar uma célula nk modificada e kit | |
NZ733855B2 (en) | Universal killer t-cell | |
CN112437668A (zh) | 通过ptp1b抑制活化细胞的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190121 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190121 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191023 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200428 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201224 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210601 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210614 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6899333 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |